RESUMEN
As other European countries, France is experiencing a resurgence of pertussis in 2024. Between 1 January and 31 May 2024, 5,616 (24.9%) positive Bordetella pertussis qPCR tests were identified, following a 3-year period of almost null incidence. Of 67 cultured and whole genome sequenced B. pertussis isolates, 66 produced pertactin and 56 produced FIM2, in contrast to pre-COVID-19 years. One isolate of genotype Bp-AgST4 was resistant to macrolides. Pertussis resurgence may favour isolates that produce FIM2 and pertactin.
Asunto(s)
Antibacterianos , Bordetella pertussis , Macrólidos , Tos Ferina , Bordetella pertussis/genética , Bordetella pertussis/aislamiento & purificación , Bordetella pertussis/efectos de los fármacos , Humanos , Francia/epidemiología , Macrólidos/farmacología , Tos Ferina/epidemiología , Tos Ferina/microbiología , Antibacterianos/farmacología , Farmacorresistencia Bacteriana , Pruebas de Sensibilidad Microbiana , Proteínas de la Membrana Bacteriana Externa/genética , Secuenciación Completa del Genoma , Factores de Virulencia de Bordetella/genética , Genotipo , Adulto , Niño , Incidencia , PreescolarRESUMEN
OBJECTIVE: To evaluate the role of Bordetella pertussis (B. pertussis), B. parapertussis, B. holmesii, and B. bronchiseptica on pertussis resurgence in China, particularly the sharp rise since the latest winter. METHODS: Nasopharyngeal swabs collected from children with pertussis-like illness from January 2018 to March 2024 were cultured to detect B. pertussis, B. parapertussis, B. holmesii, and B. bronchiseptica, and tested for all of these except for B. bronchiseptica using a pooled real-time polymerase chain reaction (PCR) kit targeting insertion sequences ptxS1, IS481, IS1001, and hIS1001. RESULTS: Out of the collected 7732 nasopharyngeal swabs, 1531 cases tested positive for B. pertussis (19.8%, 1531/7732), and 10 cases were positive for B. parapertussis (0.1%, 10/7732). B. holmesii and B.bronchiseptica were not detected. The number of specimens and the detection rate of B. pertussis were 1709 and 26.9% (459/1709) in 2018, 1936 and 20.7% (400/1936) in 2019, which sharply declined to 308 and 11.4% (35/308) in 2020, 306 and 4.2% (13/306) in 2021, and then notably increased to 754 and 17.6% (133/754) in 2022, 1842 and 16.0% (295/1842) in 2023, 877 and 22.3% (196/877) in the first quarter of 2024. The proportion of children aged 3 to less than 6 years (preschool age) and 6 to 16 years (school age) in pertussis cases increased significantly during the study period, especially the proportion of school-aged children increased from 2.0% (9/459) in 2018 to 40.8% (80/196) in 2024. CONCLUSIONS: B. pertussis was the predominant pathogen among children with pertussis-like illness in China, with sporadic detection of B. parapertussis and no detection of B. holmesii or B.bronchiseptica. The preschool and school-age children are increasingly prevalent in B. pertussis infection cases, which may be associated with the latest rapid escalation of pertussis outbreak.
Asunto(s)
Infecciones por Bordetella , Bordetella , Nasofaringe , Tos Ferina , Humanos , China/epidemiología , Preescolar , Niño , Lactante , Masculino , Femenino , Tos Ferina/epidemiología , Tos Ferina/diagnóstico , Tos Ferina/microbiología , Infecciones por Bordetella/microbiología , Infecciones por Bordetella/epidemiología , Infecciones por Bordetella/diagnóstico , Nasofaringe/microbiología , Bordetella/aislamiento & purificación , Bordetella/genética , Bordetella/clasificación , Bordetella pertussis/genética , Bordetella pertussis/aislamiento & purificación , Adolescente , Bordetella parapertussis/aislamiento & purificación , Bordetella parapertussis/genética , Reacción en Cadena en Tiempo Real de la PolimerasaAsunto(s)
Tos Ferina , Humanos , República de Corea/epidemiología , Tos Ferina/transmisión , Tos Ferina/epidemiología , Anciano , Infecciones Comunitarias Adquiridas/transmisión , Infecciones Comunitarias Adquiridas/microbiología , Infecciones Comunitarias Adquiridas/epidemiología , Persona de Mediana Edad , Anciano de 80 o más Años , Masculino , Femenino , Bordetella pertussis/aislamiento & purificación , Bordetella pertussis/genética , AdultoRESUMEN
In the United States, the general laboratory method for diagnosing pertussis, caused by Bordetella pertussis, is real-time PCR (rt-PCR) targeting insertion sequence 481 (IS481). Other Bordetella species (parapertussis, holmesii, and bronchiseptica) can also cause a pertussis-like syndrome, and some commercial laboratory assays include the insertion sequence 1001 (pIS1001) that can detect B. parapertussis/B. bronchiseptica (BppBb). Because IS481 exists in B. pertussis and B. holmesii, current commercial assays cannot differentiate these two species. We used a multiplex rt-PCR assay containing species-specific targets to Bordetella to evaluate clinical specimens detected as B. pertussis/B. holmesii (BpBh) or BppBb by commercial laboratories. A sample of 3,984 clinical specimens positive for IS481 or pIS1001 from two commercial laboratories during 2012-2019 were re-tested at CDC. Agreement of Bordetella species between the CDC and commercial laboratory assays, and the proportion of commercial laboratory specimens that were non-B. pertussis by CDC's assay was assessed. Overall agreement in Bordetella species detection and identification between the CDC and commercial lab assays was 85%. Agreement for identifying B. pertussis was 87% for 3,663 BpBh specimens and 98% for identifying B. parapertussis in 310 BppBb specimens. CDC's assay detected B. holmesii in 55/3,984 (1.4%) specimens. Most discrepant results (410/490, 82%) were BpBh specimens interpreted as indeterminate B. pertussis at CDC. We found a small portion of B. holmesii in a sample of IS481-positive clinical specimens originally identified by commercial laboratory rt-PCR assays, suggesting that commercial PCR assays are a reliable diagnostic tool for correctly identifying Bordetella species in most patients with suspected pertussis. IMPORTANCE: When testing specimens collected from patients with suspected pertussis, large-scale commercial laboratories in the United States employ an IS481-based assay that cannot differentiate between Bordetella pertussis and Bordetella holmseii. The level of B. holmesii causing pertussis-like illness in the United States is not well-understood given that only B. pertussis is nationally notifiable. After re-testing with a multiplex, species-specific rt-PCR assay, our data show low levels of B. holmesii identified in a sample of IS481-positive clinical specimens originally identified by commercial laboratory rt-PCR assays. These results reinforce the validity of large-scale commercial rt-PCR testing as a reliable diagnostic tool for pertussis in the United States.
Asunto(s)
Infecciones por Bordetella , Bordetella pertussis , Bordetella , Reacción en Cadena en Tiempo Real de la Polimerasa , Estados Unidos , Humanos , Bordetella/genética , Bordetella/clasificación , Bordetella/aislamiento & purificación , Reacción en Cadena en Tiempo Real de la Polimerasa/métodos , Infecciones por Bordetella/microbiología , Infecciones por Bordetella/diagnóstico , Bordetella pertussis/genética , Bordetella pertussis/clasificación , Bordetella pertussis/aislamiento & purificación , Tos Ferina/diagnóstico , Tos Ferina/microbiología , Reacción en Cadena de la Polimerasa Multiplex/métodos , Sensibilidad y Especificidad , Elementos Transponibles de ADN/genética , Bordetella bronchiseptica/genética , Bordetella bronchiseptica/aislamiento & purificación , Bordetella bronchiseptica/clasificaciónRESUMEN
We describe a pertussis outbreak in the Vallès region of Catalonia, from September 2023 to April 2024. Incidence was high in children aged 10-14â¯years compared with previous outbreaks. Limited impact in newborns could be explained by the high vaccination coverage during pregnancy and at 11 months of age in 2022, at 85% and 94.1 %, respectively. A third booster vaccine dose during preadolescence should be considered and vaccination coverage in pregnant women be improved to control future outbreaks.
Asunto(s)
Brotes de Enfermedades , Vacuna contra la Tos Ferina , Tos Ferina , Humanos , Tos Ferina/epidemiología , Tos Ferina/prevención & control , Tos Ferina/diagnóstico , España/epidemiología , Femenino , Adolescente , Niño , Incidencia , Lactante , Vacuna contra la Tos Ferina/administración & dosificación , Embarazo , Preescolar , Masculino , Recién Nacido , Vacunación/estadística & datos numéricos , Adulto , Cobertura de Vacunación/estadística & datos numéricos , Inmunización Secundaria , Adulto Joven , Bordetella pertussis/aislamiento & purificación , Distribución por Edad , Vigilancia de la PoblaciónRESUMEN
Bordetella pertussis is the causative pathogen of whooping cough or pertussis, a contagious respiratory disease. Aside from serodiagnosis, laboratory confirmation of pertussis is done through PCR, as B. pertussis is difficult to culture. The ELITe InGenius instrument (ELITechGroup, France) with accompanying Bordetella ELITe MGB Kit was evaluated against a laboratory-developed assay. Both assays combine two screening (IS481, IS1001) and two confirmation targets (recA, ptxA-Pr or IS1002) for optimal sensitivity and specificity. The company's stated claims on sensitivity and reproducibility were confirmed. Accuracy testing showed full concordance between both assays for the screening targets. Minor discrepancies were seen for the B. pertussis confirmation target. Some cross-reactivity with other Bordetella species was observed for the IS481-target, however, none of these were confirmed in the ptxA-Pr target. These results show the suitability of the Bordetella ELITe MGB Kit for the detection and differentiation of B. pertussis, B. parapertussis and B. holmesii.
Asunto(s)
Bordetella pertussis , Bordetella , Sensibilidad y Especificidad , Tos Ferina , Humanos , Tos Ferina/diagnóstico , Tos Ferina/microbiología , Bordetella pertussis/aislamiento & purificación , Bordetella pertussis/genética , Bordetella/aislamiento & purificación , Bordetella/clasificación , Bordetella/genética , Bordetella parapertussis/aislamiento & purificación , Bordetella parapertussis/genética , Infecciones por Bordetella/diagnóstico , Infecciones por Bordetella/microbiología , Reproducibilidad de los Resultados , Juego de Reactivos para Diagnóstico/normas , Reacción en Cadena de la Polimerasa/métodos , Técnicas de Diagnóstico Molecular/métodosRESUMEN
BACKGROUND: In 2020, the Council of State and Territorial Epidemiologists (CSTE) pertussis case definition was modified; the main change was classifying polymerase chain reaction (PCR)-positive cases as confirmed, regardless of cough duration. Pertussis data reported through Enhanced Pertussis Surveillance (EPS) in 7 sites and the National Notifiable Diseases Surveillance System (NNDSS) were used to evaluate the impact of the new case definition. METHODS: We compared the number of EPS cases with cough onset in 2020 to the number that would have been reported based on the prior (2014) CSTE case definition. To assess the impact of the change nationally, the proportion of EPS cases newly reportable under the 2020 CSTE case definition was applied to 2020 NNDSS data to estimate how many additional cases were captured nationally. RESULTS: Among 442 confirmed and probable cases reported to EPS states in 2020, 42 (9.5%) were newly reportable according to the 2020 case definition. Applying this proportion to the 6124 confirmed and probable cases reported nationally in 2020, we estimated that the new definition added 582 cases. Had the case definition not changed, reported cases in 2020 would have decreased by 70% from 2019; the observed decrease was 67%. CONCLUSIONS: Despite a substantial decrease in reported pertussis cases in the setting of coronavirus disease 2019 (COVID-19), our data show that the 2020 pertussis case definition change resulted in additional case reporting compared with the previous case definition, providing greater opportunities for public health interventions such as prophylaxis of close contacts.
Asunto(s)
Bordetella pertussis , Tos Ferina , Tos Ferina/epidemiología , Tos Ferina/diagnóstico , Tos Ferina/prevención & control , Humanos , Estados Unidos/epidemiología , Niño , Bordetella pertussis/genética , Bordetella pertussis/aislamiento & purificación , Preescolar , Lactante , Adolescente , Adulto , Adulto Joven , Masculino , Vigilancia de la Población , Femenino , Notificación de Enfermedades/estadística & datos numéricos , Reacción en Cadena de la PolimerasaRESUMEN
To determine changes in Bordetella pertussis and B. parapertussis detection rates, we analyzed 1.43 million respiratory multiplex PCR test results from US facilities from 2019 through mid-2023. From mid-2022 through mid-2023, Bordetella spp. detection increased 8.5-fold; 95% of detections were B. parapertussis. While B. parapertussis rates increased, B. pertussis rates decreased.
Asunto(s)
Infecciones por Bordetella , Bordetella parapertussis , Enfermedades Transmisibles Emergentes , Bordetella parapertussis/genética , Bordetella parapertussis/aislamiento & purificación , Estados Unidos/epidemiología , Humanos , Infecciones por Bordetella/epidemiología , Infecciones por Bordetella/microbiología , Infecciones por Bordetella/diagnóstico , Enfermedades Transmisibles Emergentes/epidemiología , Enfermedades Transmisibles Emergentes/microbiología , Bordetella pertussis/genética , Bordetella pertussis/aislamiento & purificación , Historia del Siglo XXI , Niño , Preescolar , Tos Ferina/epidemiología , Tos Ferina/microbiología , Tos Ferina/diagnóstico , Adulto , Adolescente , Lactante , Reacción en Cadena de la Polimerasa Multiplex , Adulto JovenAsunto(s)
Brotes de Enfermedades , Tos Ferina , Humanos , Tos Ferina/epidemiología , Tos Ferina/prevención & control , República Checa/epidemiología , Vacuna contra la Tos Ferina/administración & dosificación , Bordetella pertussis/aislamiento & purificación , Preescolar , Lactante , Niño , FemeninoRESUMEN
BACKGROUND: The incidence of atypical pneumonia among immunocompromised patients is not well characterized. Establishing a diagnosis of atypical pneumonia is challenging as positive tests must be carefully interpreted. We aimed to assess the test positivity rate and incidence of atypical pneumonia in transplant recipients. METHODS: A retrospective cohort study was conducted at the Yale New Haven Health System in Connecticut. Adults with solid organ transplant, hematopoietic stem cell transplant (HSCT), or chimeric antigen receptor T-cell, who underwent testing for atypical pathogens of pneumonia (Legionella pneumophilia, Mycoplasma pneumoniae, Chlamydia pneumoniae, and Bordetella pertussis) between January 2016 and August 2022 were included. Positive results were adjudicated in a clinical context using pre-defined criteria. A cost analysis of diagnostic testing was performed. RESULTS: Note that, 1021 unique tests for atypical pathogens of pneumonia were performed among 481 transplant recipients. The testing positivity rate was 0.7% (n = 7). After clinical adjudication, there were three cases of proven Legionella and one case of possible Mycoplasma infection. All cases of legionellosis were in transplant recipients within 1-year post-transplantation with recently augmented immunosuppression and lymphopenia. The possible case of Mycoplasma infection was in an HSCT recipient with augmented immunosuppression. The cost of all tests ordered was $50,797.73. CONCLUSION: The positivity rate of tests for atypical pneumonia was very low in this transplant cohort. An algorithmic approach that targets testing for those with compatible host, clinical, radiographic, and epidemiologic factors, and provides guidance on test selection and test interpretation, may improve the diagnostic yield and lead to substantial cost savings.
Asunto(s)
Huésped Inmunocomprometido , Receptores de Trasplantes , Humanos , Estudios Retrospectivos , Masculino , Persona de Mediana Edad , Femenino , Adulto , Receptores de Trasplantes/estadística & datos numéricos , Trasplante de Células Madre Hematopoyéticas/efectos adversos , Anciano , Trasplante de Órganos/efectos adversos , Incidencia , Mycoplasma pneumoniae/inmunología , Mycoplasma pneumoniae/aislamiento & purificación , Bordetella pertussis/inmunología , Bordetella pertussis/aislamiento & purificación , Chlamydophila pneumoniae/inmunología , Connecticut/epidemiologíaRESUMEN
Bordetella pertussis is a bacterial pathogen responsible for pertussis, which is a highly contagious respiratory disease. Despite the relatively high vaccination coverage, pertussis is considered a reemerging disease that necessitates enhanced strategies for identification, prevention, and control. The diagnosis of pertussis typically involves a combination of clinical evaluation, laboratory tests, and a thorough medical history. The current technologies for pertussis diagnosis have their own limitations, prompting the exploration of alternative diagnostic approaches that offer enhanced sensitivity, specificity, and speed. Microfluidic technology is considered a very promising tool for the diagnosis of infectious diseases, as it offers more rapid and accurate outputs. It allows point-of-care testing (POCT) at or near the patient site, which can be critical, especially for an outbreak or pandemic. In this paper, current pertussis diagnostic tools with their limitations were discussed, and microfluidic approaches for the diagnosis of pertussis were highlighted.
Asunto(s)
Bordetella pertussis , Pruebas en el Punto de Atención , Tos Ferina , Bordetella pertussis/aislamiento & purificación , Humanos , Tos Ferina/diagnóstico , Tos Ferina/microbiología , Sensibilidad y Especificidad , Microfluídica/métodosRESUMEN
INTRODUCTION: Cyclical pertussis epidemics primarily affect young infants. This study aims to estimate pertussis prevalence during the ongoing 2023 outbreak at our institution, focusing on affected age groups and clinical presentations. MATERIEL AND METHODS: This retrospective study includes patients admitted to Rabat University Hospital Center from 1st January 2021 to 30th June 2023. Symptomatic patients underwent Multiplex Respiratory Panel PCR testing for respiratory infections. The analysis included cases where RT-PCR identified Bordetella spp., with data analysed using SPSS 15.0. RESULTS: Pertussis cases sharply increased from December 2022, constituting 85.4 % of positive samples. Most cases (78.2 %) occurred in infants under 3 months, presenting symptoms such as coughing (94.5 %) and dyspnoea (94.5 %). Pertussis was suspected in 60 % of RT-PCR confirmed cases. B. pertussis DNA was identified in 81.8 % of cases and B. parapertussis DNA in 18.2 % of cases. CONCLUSION: The study exposes a significant pertussis outbreak affecting predominantly young infants.
Asunto(s)
Bordetella pertussis , Brotes de Enfermedades , Tos Ferina , Humanos , Tos Ferina/epidemiología , Tos Ferina/microbiología , Lactante , Estudios Retrospectivos , Masculino , Femenino , Bordetella pertussis/genética , Bordetella pertussis/aislamiento & purificación , Preescolar , Marruecos/epidemiología , Niño , Hospitalización/estadística & datos numéricos , Recién Nacido , Prevalencia , Adolescente , Bordetella parapertussis/genética , Bordetella parapertussis/aislamiento & purificaciónRESUMEN
OBJECTIVES: In Finland, whole cell pertussis vaccine (wP) was introduced in 1952 and was replaced by acellular pertussis vaccine (aP) without fimbrial (FIM) antigen in 2005. We aimed to analyse the changes in serotypes of circulating Bordetella pertussis before and after acellular vaccination and to explore the relationship between biofilm formation and serotype diversity after the introduction of aP vaccine. METHODS: Serotyping of 1399 B. pertussis isolates collected at the Finnish National Reference Laboratory for Pertussis and Diphtheria in Turku, Finland, from 1974 to 2023 was performed by slide agglutination or indirect ELISA. Of 278 isolates collected after 2005, 53 were selected, genotyped for fim3 and fim2 alleles, and tested for biofilm formation. The selection criteria included maintaining a relatively equal distribution of isolates per time interval, ensuring approximately a 50:50 ratio of FIM2 (N = 26) and FIM3 (N = 27) serotypes. The reference strain Tohama I was used as a control. RESULTS: During the wP era, the majority of circulating B. pertussis exhibited the FIM2 serotype. However, FIM3 strains have appeared since 1999 and become prevalent. After the implementation of aP vaccines, the distribution of serotypes has exhibited substantial variability. FIM3 isolates displayed an enhanced biofilm formation compared to FIM2 isolates (Geometric mean value (95% CI): 0.90 (0.79-1.03) vs. 0.75 (0.65-0.85); p < 0.05). Of the 27 FIM3 isolates, 8 harboured fim3-1 and 19 fim3-2 alleles. FIM3 isolates with fim3-2 allele were significantly associated with increased biofilm formation when compared to those with fim3-1 (1.07 (0.96-1.19) vs. 0.61 (0.52-0.72); p < 0.0001). CONCLUSION: Following the implementation of aP vaccines, the distribution of serotypes in Finland has exhibited substantial variability. FIM3 isolates with the fim3-2 allele displayed an enhanced biofilm formation capability compared to FIM2 isolates.
Asunto(s)
Antígenos Bacterianos , Biopelículas , Bordetella pertussis , Serogrupo , Factores de Virulencia de Bordetella , Tos Ferina , Biopelículas/crecimiento & desarrollo , Finlandia/epidemiología , Bordetella pertussis/genética , Bordetella pertussis/clasificación , Bordetella pertussis/inmunología , Bordetella pertussis/aislamiento & purificación , Humanos , Tos Ferina/microbiología , Tos Ferina/epidemiología , Tos Ferina/prevención & control , Vacuna contra la Tos Ferina/inmunología , Vacuna contra la Tos Ferina/administración & dosificación , Vacunas Acelulares/inmunología , Proteínas Fimbrias/genética , Proteínas Fimbrias/inmunología , Serotipificación , Genotipo , Preescolar , Niño , Lactante , VacunaciónRESUMEN
Next-generation whole-genome sequencing is essential for high-resolution surveillance of bacterial pathogens, for example, during outbreak investigations or for source tracking and escape variant analysis. However, current global sequencing and bioinformatic bottlenecks and a long time to result with standard technologies demand new approaches. In this study, we investigated whether novel nanopore Q20+ long-read chemistry enables standardized and easily accessible high-resolution typing combined with core genome multilocus sequence typing (cgMLST). We set high requirements for discriminatory power by using the slowly evolving bacterium Bordetella pertussis as a model pathogen. Our results show that the increased raw read accuracy enables the description of epidemiological scenarios and phylogenetic linkages at the level of gold-standard short reads. The same was true for our variant analysis of vaccine antigens, resistance genes, and virulence factors, demonstrating that nanopore sequencing is a legitimate competitor in the area of next-generation sequencing (NGS)-based high-resolution bacterial typing. Furthermore, we evaluated the parameters for the fastest possible analysis of the data. By combining the optimized processing pipeline with real-time basecalling, we established a workflow that allows for highly accurate and extremely fast high-resolution typing of bacterial pathogens while sequencing is still in progress. Along with advantages such as low costs and portability, the approach suggested here might democratize modern bacterial typing, enabling more efficient infection control globally.
Asunto(s)
Bacterias , Genoma Bacteriano , Técnicas de Genotipaje , Tipificación de Secuencias Multilocus , Secuenciación de Nanoporos , Antígenos Bacterianos/genética , Bacterias/genética , Bacterias/aislamiento & purificación , Bacterias/patogenicidad , Vacunas Bacterianas/genética , Bordetella pertussis/genética , Bordetella pertussis/aislamiento & purificación , Bordetella pertussis/patogenicidad , Farmacorresistencia Bacteriana/genética , Monitoreo del Ambiente , Secuenciación de Nucleótidos de Alto Rendimiento/métodos , Tipificación de Secuencias Multilocus/métodos , Secuenciación de Nanoporos/métodos , Filogenia , Reproducibilidad de los Resultados , Factores de Virulencia/genéticaRESUMEN
Whooping cough, the respiratory disease caused by Bordetella pertussis, has undergone a wide-spread resurgence over the last several decades. Previously, we developed a pipeline to assemble the repetitive B. pertussis genome into closed sequences using hybrid nanopore and Illumina sequencing. Here, this sequencing pipeline was used to conduct a more high-throughput, longitudinal screen of 66 strains isolated between 1982 and 2018 in New Zealand. New Zealand has a higher incidence of whooping cough than many other countries; usually at least twice as many cases per 100000 people as the USA and UK and often even higher, despite similar rates of vaccine uptake. To the best of our knowledge, these strains are the first New Zealand B. pertussis isolates to be sequenced. The analyses here show that, on the whole, genomic trends in New Zealand B. pertussis isolates, such as changing allelic profile in vaccine-related genes and increasing pertactin deficiency, have paralleled those seen elsewhere in the world. At the same time, phylogenetic comparisons of the New Zealand isolates with global isolates suggest that a number of strains are circulating in New Zealand, which cluster separately from other global strains, but which are closely related to each other. The results of this study add to a growing body of knowledge regarding recent changes to the B. pertussis genome, and are the first genetic investigation into B. pertussis isolates from New Zealand.
Asunto(s)
Bordetella pertussis/clasificación , Genómica/métodos , Secuenciación Completa del Genoma/métodos , Tos Ferina/epidemiología , Bordetella pertussis/genética , Bordetella pertussis/aislamiento & purificación , Genoma Bacteriano , Secuenciación de Nucleótidos de Alto Rendimiento , Humanos , Incidencia , Secuenciación de Nanoporos , Nueva Zelanda/epidemiología , FilogeniaRESUMEN
From 2015 to 2017, 3197 interpretable Bordetella polymerase chain reaction (PCR) tests were performed for 2760 children presenting to our tertiary university hospital. Requests mainly came from the emergency department (62%) and for children older than 1 year (68%). Only 32 PCR (1%) results were positive, mainly in children younger than 1 year (n = 29/32, 90.6%; p<0.001). When focusing on the PCR indications in 2017, we found the requests were mainly based on nonspecific respiratory symptoms and were clinically unjustified in 383 cases (39%). Pediatricians overused Bordetella PCR in clinical practice. They should reserve their requests for cases of young children with symptoms suggestive of respiratory illness and/or incomplete pertussis immunization.
Asunto(s)
Bordetella pertussis/genética , Tos/etiología , Uso Excesivo de los Servicios de Salud , Tos Ferina/diagnóstico , Anticuerpos Antibacterianos/sangre , Bordetella pertussis/inmunología , Bordetella pertussis/aislamiento & purificación , Niño , Preescolar , ADN Bacteriano/aislamiento & purificación , Femenino , Francia , Hospitales , Humanos , Lactante , Masculino , Reacción en Cadena de la PolimerasaRESUMEN
The purpose of this study is to understand children's clinical characteristics with pertussis and analyze risk factors on critical pertussis patients. Demographic data from patients with pertussis at Children's Hospital affiliated to the Capital Institute of Pediatrics between March 2011 and December 2018 were collected. We retrospectively gathered more information with the positive exposure, vaccination, antibiotic usage before diagnosis, clinical manifestation, laboratory tests, therapy, and complications for hospitalized children. We divided the patients into severe and non-severe groups, comparing related factors and clinical characteristics among each group. In particular, we summarize the clinical features of the severe patients before aggravation. A total of 967 pertussis cases were diagnosed, of which 227 were hospitalized. The onset age younger than 3 months old accounted for the highest proportion, and 126 patients received hospitalization. For those patients, the incidence of post-tussive vomiting, paroxysmal cyanosis, post-tussive heart rate decrease, hypoxemia, severe pneumonia, and mechanical ventilation was significantly higher than that in the ≥ 3-month-old group (p < 0.05). Among 227 hospitalized patients, 54 suffered from severe pertussis. Risk factors for severe patients included early age of onset, pathogen exposure, and unvaccinated status. Cough paroxysms, post-tussive vomiting, paroxysmal cyanosis, facial flushing/cyanosis/fever during cough, increased WBC, and chest X-ray revealing pneumonia/consolidation/atelectasis were important indications of severe pertussis. Unvaccinated status was an independent risk factor for severe pertussis. The most vulnerable population was infants < 3 months old to pertussis, and may be on the severe end of the disease. Pediatricians must detect and treat severe cases promptly and recommend timely vaccination for all eligible children.
Asunto(s)
Tos Ferina/diagnóstico , Tos Ferina/epidemiología , Adolescente , Beijing/epidemiología , Bordetella pertussis/clasificación , Bordetella pertussis/genética , Bordetella pertussis/aislamiento & purificación , Niño , Preescolar , Femenino , Hospitalización , Hospitales Pediátricos , Humanos , Lactante , Masculino , Estudios Retrospectivos , Tos Ferina/microbiología , Tos Ferina/terapiaRESUMEN
Despite great advances in describing Bordetella pertussis infection, the role of the host microbiota in pertussis pathogenesis remains unexplored. Indeed, the microbiota plays important role in defending against bacterial and viral respiratory infections. We investigated the nasopharyngeal microbiota in infants infected by B. pertussis (Bp), Rhinovirus (Rv) and simultaneously by both infectious agents (Bp + Rv). We demonstrated a specific nasopharyngeal microbiome profiles for Bp group, compared to Rv and Bp + Rv groups, and a reduction of microbial richness during coinfection compared to the single infections. The comparison amongst the three groups showed the increase of Alcaligenaceae and Achromobacter in Bp and Moraxellaceae and Moraxella in Rv group. Furthermore, correlation analysis between patients' features and nasopharyngeal microbiota profile highlighted a link between delivery and feeding modality, antibiotic administration and B. pertussis infection. A model classification demonstrated a microbiota fingerprinting specific of Bp and Rv infections. In conclusion, external factors since the first moments of life contribute to the alteration of nasopharyngeal microbiota, indeed increasing the susceptibility of the host to the pathogens' infections. When the infection is triggered, the presence of infectious agents modifies the microbiota favoring the overgrowth of commensal bacteria that turn in pathobionts, hence contributing to the disease severity.